<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690053</url>
  </required_header>
  <id_info>
    <org_study_id>08-3-040</org_study_id>
    <nct_id>NCT00690053</nct_id>
  </id_info>
  <brief_title>Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET)</brief_title>
  <acronym>HX-4</acronym>
  <official_title>Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PAT): A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non invasive imaging of hypoxia with the aid of PET-scans could help to select the patients
      having a hypoxic tumour who could be treated with specific anti-hypoxic treatments such as
      bio-reductive drugs or hypoxic radio-sensitizers. Several 2-nitroimidazoles to which the
      compound to be tested, HX-4, belongs, labelled with Fluor-18 have already been used in
      patients. However, bad image quality and unpredictable kinetics limit their use. In extensive
      pre-clinical models, the combination of HX-4 labelled with Fluor-18 is a promising non-toxic
      new probe to determine hypoxia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the toxicity of the hypoxia PET-tracer [18F]-HX4 in cancer patients in two
      dose-steps:

        -  Step 1 (3-6 patients): a single dose of maximum 6 mCi (222 MBq) dose of [18F]HX4 (which
           contains a maximum of 15 μg HX-4) via a bolus IV injection.

        -  Step 2 (3-6 patients): a single dose of maximum 12 mCi (444 MBq) dose of [18F]HX4 (which
           contains a maximum of 27 μg HX-4) via a bolus IV injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity (CTCAE 3.0)</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image Quality at different time points (Tumour-to-Background Ratio determined by PET-CT scan)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Injection of HX-4</intervention_name>
    <description>In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmed solid tumour, primary or secondary stage IV and/
             or tumours with no curative treatment options.

          -  Normal white blood cell count and neutrophils

          -  Normal platelet count

          -  No anaemia requiring blood transfusion or erythropoietin

          -  Adequate hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for the
             institution; ALT, AST, and alkaline phosphatase ≤ 2.5 x ULN for the institution).

          -  Calculated Creatinin clearance at least 60 ml/min

          -  No administration of Fluor-18 in the previous 24 hours

          -  Capable of complying with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology (MAASTRO clinic)</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>June 29, 2009</last_update_submitted>
  <last_update_submitted_qc>June 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>dr. D.K.M. De Ruysscher</name_title>
    <organization>Maastro Clinic</organization>
  </responsible_party>
  <keyword>Toxicity</keyword>
  <keyword>PET</keyword>
  <keyword>HX-4</keyword>
  <keyword>cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

